In today’s Pharma Pulse, SOBI strengthens its gout franchise by acquiring Arthrosi Therapeutics for up to $1.5 billion, ...

Cheryl Allen, BS Pharm, MBA, founding partner, highlights the coming year's focus on navigating an evolving regulatory ...

At a time when investors are questioning the sustainability of pharmaceutical business models, reliable execution has become ...

Modern PBMs, or PBM-like functions, should operate with full line-of-sight to net price and patient outcomes. Full ...

Although he typically revises his macro framework only once every decade or more, Roth explained that the current environment ...

One of which revolved around “Optimizing GTN Strategy—Balancing Channel Economics and Market Access,” led by Lannett ...

In today’s Pharma Pulse, the FDA approves Amgen’s Uplizna (inebilizumab-cdon), the first CD19-targeted therapy for gMG with convenient twice-yearly dosing, and much more.

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, ...

Cheryl Allen, BS Pharm, MBA, founding partner, Curatio Scientia Advisors, hopes to use the conference to explore how ...

As the FDA ends its phased exemption period for most trading partners, Two Labs’ Michael Rowe warns that DSCSA compliance is ...

Counterfeit pharma networks are becoming more sophisticated—leveraging advanced packaging, fragmented logistics, and global ...

In today’s Pharma Pulse, the University of Maryland expands its medical class to combat physician shortages and much more.